Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

This study has been completed.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Abbott
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00181558
First received: September 9, 2005
Last updated: May 7, 2010
Last verified: May 2010
  Purpose

The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread to the bones.


Condition Intervention Phase
Prostate Cancer
Adenocarcinoma of the Prostate
Drug: Atrasentan
Drug: Zoledronic Acid (Zometa)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • To compare the effects of Atrasentan monotherapy with combination therapy using Atrasentan and Zometa on bone specific alkaline phosphatase.

Secondary Outcome Measures:
  • To evaluate the effects of Atrasentan monotherapy and combination therapy with Atrasentan and Zometa on PSA doubling time.

Estimated Enrollment: 44
Study Start Date: December 2001
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Detailed Description:
  • Patients will be randomized to either receive Atrasentan alone or Atrasentan plus Zometa.
  • Patients receiving Atrasentan alone will receive this drug in pill form once daily for 12 weeks. Patients will have a physical exam, blood work, and a urine sample performed once every other week during the first four weeks of medication administration. After those two initial visits, they will return to the clinic once every 4 weeks to have the same tests repeated. A bone scan and abdominal-pelvic CT Scan will be done every 12 weeks.
  • After the patient has been taking Atrasentan for 12 weeks, if the disease has not progressed, they will begin combination treatment of Atrasentan and Zometa.
  • Patients receiving Atrasentan plus Zometa, receive Zometa intravenously and then immediately start Atrasentan orally once daily as long as they remain on the study. Patients will return to the clinic twice over the first 4 weeks (once every other week) to have a physical exam, blood work and urine test performed. After these two initial visits, they will return to the clinic once every 4 weeks to have the tests repeated and to receive another treatment of zometa. A bone scan and an abdominal-pelvic CT Scan will be done once every 12 weeks.
  • Patients participation in this study will last as long as the disease does not progress and they are not experiencing any serious side effects.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate
  • History of bilateral orchiectomy or current treatment with a GnRH agonist or antagonist
  • Radiographically documented bone metastases
  • Disease progression according to criteria from the PSA Working Group

Exclusion Criteria:

  • Prior treatment with Atrasentan or Zometa within one year
  • Serum creatinine > 2.0mg/dL
  • Documented cardiovascular disability status of New York Heart Association Class 2
  • Treatment with chemotherapy, radiation, steroids, estrogens, or PC-SPES within 6 weeks
  • Treatment with bisphosphonates or radiopharmaceuticals within 12 weeks
  • History of Paget's disease, hyperthyroidism, hyperparathyroidism, Cushing's syndrome, hyperprolactinemia or other disorder associated with metabolic bone disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00181558

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Abbott
Investigators
Principal Investigator: Matthew Smith, MD, PhD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Matthew R. Smith, MD, PhD, Massachusetts General Hospital, Boston, MA 02114
ClinicalTrials.gov Identifier: NCT00181558     History of Changes
Other Study ID Numbers: 01-200
Study First Received: September 9, 2005
Last Updated: May 7, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Prostate Cancer
bone metastases
Atrasentan
Zometa
Androgen Independent Prostate Cancer

Additional relevant MeSH terms:
Adenocarcinoma
Prostatic Neoplasms
Bone Neoplasms
Bone Marrow Diseases
Neoplasm Metastasis
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Bone Diseases
Musculoskeletal Diseases
Hematologic Diseases
Neoplastic Processes
Pathologic Processes
Androgens
Zoledronic acid
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on April 15, 2014